ClinicalTrials.gg
RecruitingNCT06649162Updated Oct 18, 2024

A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy

An observational study in Type 2 Diabetes, sponsored by Boryung Pharmaceutical Co., Ltd. Recruiting at 2 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-10-18.

Sponsored by Boryung Pharmaceutical Co., Ltd · Observational

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies in Diabetes Mellitus, Type 2 by Boryung Pharmaceutical Co., Ltd — 3 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Boryung Pharmaceutical Co., Ltd.

Started
2024
with 9 others
Observational
Only one
of the 14
Registered
9th of 14
by date

Among the 14 studies in Diabetes Mellitus, Type 2 by Boryung Pharmaceutical Co., Ltd, this one is one of 10 that started in 2024, is the only observational one, and was the 9th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 14 studies in Diabetes Mellitus, Type 2 by Boryung Pharmaceutical Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diabetes Mellitus, Type 2 by Boryung Pharmaceutical Co., Ltd, or all of them as a file.
02

Study summary

The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with type 2 diabetes scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
  • Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.

Exclusion criteria

Exclusion Criteria:

  • Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1).
  • Those who are expected to need insulin prescription during the study period.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Percentage of subjects who correspond to high risk score (≥8) by evaluating simple NAFLD score

    Time frame: Baseline (visit 1)

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Mar 2027, 30 months after the start.

Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's planned 30 months is above that.

Counting every sponsor, half of 604 studies reached it within 32 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2024
First posted
Oct 18, 2024
StartActual
Sep 30, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Oct 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06649162
Responsible party
Sponsor
First posted
Oct 18, 2024
Start date
Sep 30, 2024
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 18, 2024

Study contacts

Shin-young Oh
Contact
syoh@boryung.co.kr
+82-2-708-8000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion